The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $2.59 for the day, down -7.83% from the previous closing price of $2.81. In other words, the price has decreased by -$7.83 from its previous closing price. On the day, 3.0 million shares were traded. CCCC stock price reached its highest trading level at $2.75 during the session, while it also had its lowest trading level at $2.57.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.76 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.36.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $8.
Stephens Upgraded its Equal-Weight to Overweight on September 15, 2025, while the target price for the stock was maintained at $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 251008336 and an Enterprise Value of 120587344. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.34 while its Price-to-Book (P/B) ratio in mrq is 1.24. Its current Enterprise Value per Revenue stands at 4.005 whereas that against EBITDA is -1.03.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.91, which has changed by -0.3642534 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $5.10, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is 7.83%, while the 200-Day Moving Average is calculated to be 23.60%.
Shares Statistics:
CCCC traded an average of 2.03M shares per day over the past three months and 1453740 shares per day over the past ten days. A total of 96.91M shares are outstanding, with a floating share count of 77.61M. Insiders hold about 19.92% of the company’s shares, while institutions hold 57.44% stake in the company. Shares short for CCCC as of 1763078400 were 4848155 with a Short Ratio of 2.39, compared to 1760486400 on 3987152. Therefore, it implies a Short% of Shares Outstanding of 4848155 and a Short% of Float of 5.29.
Earnings Estimates
The firm’s stock currently is rated by 3.0 analysts. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.33 and -$1.71 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$1.29, with 3.0 analysts recommending between -$1.15 and -$1.55.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $8M to a low estimate of $100k. As of. The current estimate, C4 Therapeutics Inc’s year-ago sales were $5.18M
A total of 6 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $35M, while the lowest revenue estimate was $25M, resulting in an average revenue estimate of $30.39M. In the same quarter a year ago, actual revenue was $35.58M
